In a nutshell
This study evaluated the progress made in the survival of pediatric patients with acute myeloid leukemia (AML) in the Netherlands. Researchers concluded that recent progress in the treatment of AML has improved survival in this group of patients.
Some background
Acute myeloid leukemia (AML) is a cancer that can commonly affect children and young people. Treatment involves strong chemotherapy and drugs which target abnormal genes in the immune system. This is an ongoing area of active research. It is important to assess progress in treatment and survival of young patients with acute leukemia.
Methods & findings
635 patients diagnosed with AML in the Netherlands over the past 25 years were included in this study. Survival outcomes over time were analyzed.
The 5-year overall survival has significantly improved from 40% in the early 1990s to 74% in 2010-2015. There has been a 49% reduction in risk of death for patients who underwent treatment according to the currently available protocol. Death rates have decreased by 2.8% per year.
The bottom line
The study concluded that outcomes have significantly improved for young patients with AML in the Netherlands.
The fine print
This study was based in the Netherlands. Other countries may use different treatment protocols.
Published By :
Leukemia
Date :
Dec 19, 2018
